A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Cemdisiran (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
- 01 Apr 2024 Results assessing efficacy and safety of cemdisiran in adult patients with IgA nephropathy at high risk of kidney disease progression published in the Clinical Journal of The American Society of Nephrology: CJASN
- 07 Dec 2023 Status changed from active, no longer recruiting to discontinued early having identified clinically meaningful magnitude of proteinuria reduction due to cemdisiran (study goal). Participants completed DBT period & were in OLE period. Sponsor had no concerns with safety &integrity of participants.
- 09 Oct 2023 This trial has been discontinued in Sweden, according to European Clinical Trials Database record.